Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
AssigneeImmunomedics, Inc.
InventorDavid M. Goldenberg
Life of this patent
Estimating the term…
Abstract
The present invention relates to immunotoxins that effectively kill malignant cells having a given marker. The immunotoxins are reagents that comprise internalizing antibodies conjugated to cytotoxic ribonucleases or fragments thereof. The internalizing antibodies are capable of binding with a chosen tumor cell, and thereby confer little non-specific toxicity to the immunotoxin in a host. The immunotoxins exhibit up to 2000-fold higher toxicity against malignant B cells than did the ribonuclease counterparts alone.
Claims140
A cytotoxic reagent comprising an antibody and a moiety having ribonucleolytic activity derived from a non-human ribonuclease, wherein said antibody and said moiety are linked through recombinant production.
A cytotoxic reagent comprising an internalizing antibody and a moiety having ribonucleolytic activity, wherein said internalizing antibody is directed against a lineage-dependent antigen or against an antigen associated with cancer cells, and wherein said internalizing antibody and said moiety are linked through recombinant production.
A cytotoxic reagent comprising an antibody and a moiety having ribonucleolytic activity derived from a non-human ribonuclease, wherein said antibody is directed against an antigen other than a B-cell antigen.
A cytotoxic reagent comprising an internalizing antibody and a moiety having ribonucleolytic activity, wherein said internalizing antibody is directed against a lineage-dependent antigen or against an antigen associated with cancer cells, and wherein said internalizing antibody is directed against an antigen selected from the group consisting of:
- a) T-cell antigens;
- (b) MUC1 antigens;
- (c) EGP-1 antigens;
- (d) EGP-2 antigens;
- and
- (e) placental alkaline phosphatase antigen.
A cytotoxic reagent comprising an antibody and a moiety having ribonucleolytic activity derived from a non-human ribonuclease, wherein said antibody is human or humanized.
A cytotoxic reagent comprising an internalizing antibody and a moiety having ribonucieolytic activity, wherein said internalizing antibody is directed against a lineage-dependent antigen or against an antigen associated with cancer cells, and wherein said internalizing antibody is human or humanized.
Dependencies are inferred from the claim text.